Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
Top Cited Papers
Abstract
No abstract availableKeywords
Funding Information
- Johnson and Johnson
- National Center for Advancing Translational Sciences
- National Institutes of Health (UL1TR002489)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30 AR072520-01)
- National Heart, Lung, and Blood Institute (5T32 HL007106-43)
This publication has 36 references indexed in Scilit:
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline UpdateJournal of Clinical Oncology, 2020
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2019
- The role of immunotherapy in small cell lung cancerClinical and Translational Oncology, 2019
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenNew England Journal of Medicine, 2018
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic reviewAnnals of Oncology, 2017
- Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-AnalysisThe Oncologist, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015